2024/11/01 08:13:39 | |
---|---|
Price | |
10.66 EUR | |
Difference | -0.28% (-0.03) |
ISIN | JP3942400007 |
Symbol | 4503 |
Exchange | Stuttgart |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 19,284 EUR |
Benchmark | NIKKEI 225 |
Bid (Bid size) | 10.71 EUR (1,000) |
Ask (Ask size) | 10.945 EUR (1,000) |
Open | 10.66 EUR |
High | 10.66 EUR |
Low | 10.66 EUR |
Close (prev. day) | 10.69 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/10/29 | Global Equity Ratings | ||
2024/10/29 | Aktienempfehlungen Global | ||
2024/10/22 | Global Equity Ratings | ||
2024/10/22 | Aktienempfehlungen Global | ||
2024/10/14 | Aktienempfehlungen Österreich |
2024/11/01 08:13:39 | |
---|---|
Price | |
10.66 EUR | |
Difference | -0.28% (-0.03) |
ISIN | JP3942400007 |
Symbol | 4503 |
Exchange | Stuttgart |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 19,284 EUR |
Benchmark | NIKKEI 225 |
Bid (Bid size) | 10.71 EUR (1,000) |
Ask (Ask size) | 10.945 EUR (1,000) |
Open | 10.66 EUR |
High | 10.66 EUR |
Low | 10.66 EUR |
Close (prev. day) | 10.69 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
6M | 1Y | 3Y | |
Perf (%) | +18.75% | -9.64% | -25.58% |
Perf (abs.) | +1.69 | -1.14 | -3.68 |
Beta | 0.30 | 0.29 | 0.47 |
Volatility | 28.20 | 29.22 | 27.16 |
Ø price 5 days | Ø volume 5 days (pcs.) | 10.58 EUR (10) |
Ø price 30 days | Ø volume 30 days (pcs.) | 10.58 EUR (70) |
Ø price 100 days | Ø volume 100 days (pcs.) | 10.24 EUR (58) |
Ø price 250 days | Ø volume 250 days (pcs.) | 10.13 EUR (185) |
YTD High | date | 11.41 EUR (2024/01/16) |
YTD Low | date | 8.68 EUR (2024/05/17) |
52 Weeks High | date | 11.77 EUR (2023/11/03) |
52 Weeks Low | date | 8.68 EUR (2024/05/17) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Tradegate | 2024/11/01 | 09:30 | 10.95 EUR | 0.00 | 1 |
Tokyo Stock Exchange | 2024/11/01 | 07:00 | 1,781.50 JPY | 86.47 | 5,625 |
Stuttgart | 2024/11/01 | 08:13 | 10.66 EUR | 0.00 | 1 |
Munich | 2024/11/01 | 08:03 | 10.745 EUR | 0.00 | 1 |
Frankfurt | 2024/11/01 | 09:06 | 10.485 EUR | 0.00 | 1 |
FINRA other OTC Issues | 2024/10/31 | 15:23 | 11.1275 USD | 0.01 | 2 |
Duesseldorf | 2024/11/01 | 09:31 | 10.68 EUR | 0.00 | 2 |
Berlin | 2024/11/01 | 10:05 | 10.83 EUR | 0.00 | 3 |
ASTELLAS PHARMA INC. |
- - |
2-5-1 Nihonbashi-Honcho, Chuo-Ku - 103-8411 Tokyo |
Telefon: +81-3-3244-3000 |
Fax: + |
E-mail: - |
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan. |
Kenji Yasukawa | Chairman of Managing Board |
Bernie Zeiher | Member of Executive Committee |
Catherine Levitt | Member of Executive Committee |
Fumiaki Sakurai | Member of Executive Committee |
Hideki Shima | Member of Executive Committee |
Minoru Kikuoka | Member of Executive Committee |
Naoki Okamura | Member of Executive Committee |
Yoshihtsugu Shitaka | Member of Executive Committee |
Yukio Matsui | Member of Executive Committee |
Kenji Yasukawa | Chairman of Supervisory Board |
Eriko Sakurai | Member of Supervisory Board |
Haruko Shibumura | Member of Supervisory Board |
Hiroko Sakai | Member of Supervisory Board |
Hiroo Sasaki | Member of Supervisory Board |
Hiroshi Kawabe | Member of Supervisory Board |
Katsuyoshi Sugita | Member of Supervisory Board |
Mamoru Sekiyama | Member of Supervisory Board |
Mika Nakayama | Member of Supervisory Board |
Noriyuki Uematsu | Member of Supervisory Board |
Takashi Tanaka | Member of Supervisory Board |
Tatsuro Ishizuka | Member of Supervisory Board |
Tomokazu Fujisawa | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Erste Group Bank AG or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites”) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions (the “Interested Party“).
The publication and distribution of information as well as offering and selling of products and services described on the Websites is prohibited by law in some jurisdictions. For this reason, persons in countries in which the publication as well as the offering and selling of products and services described on the Websites are not permitted by law, must not enter the Websites and/or acquire the products displayed on the Websites.
Neither Erste Group nor any third party shall offer access to the Websites or offer the products to especially, but not limited to citizen/residents of the United States and “U.S. person” (as defined in Regulation S under the US Securities Act 1933 as amended). For this reason, the distribution or redistribution of the information, materials and products into United States or into any other jurisdiction where it is not permitted under the applicable law, as well as to the citizens/residents of these countries shall be prohibited. The securities displayed on the Websites have not been and will not be registered under the US Securities Act of 1933 and trading in the securities has not been approved for purposes of the US Commodities Exchange Act of 1936. For this reason the securities may, inter alia, not be offered, sold or delivered within the United States or, for the account and benefit of U.S. persons.
The Interested Party is solely responsible to examine, whether he may enter the Websites under the law applicable to it. Erste Group shall not be responsible for the distribution of content of any of the Websites to individuals or entities which provide false information about their right to enter the Websites. For this reason Erste Group shall not be liable for any legal claims or damages which may result from the unauthorized entering or reading of the Websites.
By agreeing to this hereto, the Interested Party confirms that
(i) It has read, understood and accepted this Information and the Disclaimer;
(ii) It informed itself about any possible legal restriction and warrants that it is not restricted or prohibited to enter the Websites according to any law applicable; and
(iii) It does not make available the contents of the Websites to any person who is not qualified by law to enter the Websites.